Viewing nowCombinationGlossitapomin Tablets 50/1000 milligrams
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.

MFDS item code 202300845 · Approved 2023.03.13 · Insurance code 693202560
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as an adjunct to dietary and exercise therapy to improve blood sugar control in patients with type 2 diabetes. The combination of sitagliptin and metformin effectively manages blood sugar levels and aids in the treatment of diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who do not achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current dose of metformin. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this medicine should not be initiated because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication consists of sitagliptin and metformin and is primarily used for the treatment of type 2 diabetes. While taking this medicine, severe allergic reactions may occur, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, immediately stop use and seek medical attention. Additionally, this medication may pose a risk of acute pancreatitis, which causes inflammation of the pancreas, so if symptoms such as sudden abdominal pain, vomiting, or fever occur, inform a healthcare provider immediately. Patients with severely impaired kidney function or those with serious infections or dehydration should not use this medication, and its use should be discontinued for a certain period before and after tests using iodinated contrast agents. It is also safe for women who are pregnant or may become pregnant, as well as nursing mothers, to avoid this medication. This medication can cause a rare but serious side effect known as lactic acidosis, in which lactic acid builds up in the body, and symptoms may include muscle pain, weakness, difficulty breathing, abdominal pain, and confusion. If these symptoms occur, immediate medical attention is necessary. Regular kidney function and blood tests are recommended during treatment, and Vitamin B12 levels should also be monitored periodically. Furthermore, when used with other blood sugar-lowering medications or insulin, the risk of hypoglycemia may increase, so it is important to closely monitor blood sugar changes. Excessive alcohol consumption, intense exercise, or irregular eating patterns may increase the risk of hypoglycemia or other side effects, so they should be avoided. If surgery is planned, this medication should be discontinued 48 hours before the procedure and resumed only after confirming that kidney function is normal following recovery. During treatment, there is a potential for drug interactions, so inform a doctor or pharmacist if taking other medications. Finally, it is not recommended for use in children and adolescents under 18 years of age as its safety and efficacy have not been adequately established.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture from entering, and it is best stored at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the medication's efficacy.
Brownish-red oval film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.